Trial reportBMC health services research2025
Patients' and providers' perspectives of a dose administration aid strategy to improve cardiovascular disease prevention in Australian primary healthcare.
Trial report in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHypertension is the most commonly managed problem in general practice in Australia, but blood pressure control is not achieved for most patients. An important factor to consider in hypertension control is patient medication adherence. Use of dose administration aids (DAAs) could increase adherence to medicines and reduce the frequency of medication errors. We conducted a trial to evaluate adherence to DAAs in real-world conditions. This study is a process evaluation of the main trial. This stydy aims to understand the acceptability of DAAs from patients, providers, and carers perspectives and examine implementation barriers and facilitators of trial processes.
methodsIn-depth, semi structured interviews were conducted in an Australian general practice participating in a pilot randomised controlled trial evaluating a DAA-based strategy for people with high-risk primary and secondary cardiovascular disease. Interview topics included DAA acceptability, factors affecting adherence and trial implementation. Transcribed interview data were analysed thematically and interpretively. The consolidated framework for implementation research was used to guide our analysis.
resultsNineteen interviews were conducted (16 participants or carers, 1 physician, 1 pharmacist and 1 DAA packaging company representative). All trial participants reported improved adherence, especially in those with prior poor adherence. Key barriers to DAA use included inertia to change, resistance from the pharmacist with regards to repackaging by an external provider, logistics of direct home delivery and lack of communication. A key facilitator to trial implementation was the therapeutic relationship of patients with the health care professionals.
conclusionThe DAA strategy was generally acceptable to patients and the physician as a cardiovascular preventative strategy. Participants suggested a DAA-based strategy as particularly appropriate for those with prior poor adherence to medications.
trial registrationACTRN12620001239954. 19/11/2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.